Harrow Eye Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HARROW EYE, and what generic alternatives to HARROW EYE drugs are available?
HARROW EYE has nineteen approved drugs.
There are twenty-nine US patents protecting HARROW EYE drugs.
There are three hundred and fifty-five patent family members on HARROW EYE drugs in forty-two countries and twenty-five supplementary protection certificates in ten countries.
Summary for Harrow Eye
| International Patents: | 355 |
| US Patents: | 29 |
| Tradenames: | 18 |
| Ingredients: | 15 |
| NDAs: | 19 |
Drugs and US Patents for Harrow Eye
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | 8,298,568 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | ILEVRO | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 203491-001 | Oct 16, 2012 | RX | Yes | Yes | 8,921,337 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | ILEVRO | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 203491-001 | Oct 16, 2012 | RX | Yes | Yes | 7,947,295 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Harrow Eye
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | VEXOL | rimexolone | SUSPENSION/DROPS;OPHTHALMIC | 020474-001 | Dec 30, 1994 | 4,686,214 | ⤷ Sign Up |
| Harrow Eye | ILEVRO | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 203491-001 | Oct 16, 2012 | 5,475,034 | ⤷ Sign Up |
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | 4,517,199 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HARROW EYE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 10.5% | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Ophthalmic Suspension | 0.3% | ➤ Subscribe | 2015-12-21 |
| ➤ Subscribe | Ophthalmic | 0.50% | ➤ Subscribe | 2005-12-22 |
International Patents for Harrow Eye Drugs
Supplementary Protection Certificates for Harrow Eye Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0350733 | 2001C/030 | Belgium | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 0716600 | C00716600/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008 |
| 2049079 | LUC00006 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
